Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bezlotoxumab - Merck & Co

Drug Profile

Bezlotoxumab - Merck & Co

Alternative Names: CDB1; Clostridium difficile toxin B monoclonal antibody; MBL-CDB1; MDX-1388; MK 6072; Zinplava

Latest Information Update: 04 Nov 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medarex; University of Massachusetts Medical School
  • Developer Merck & Co; Merck Sharp & Dohme
  • Class Antidiarrhoeals; Monoclonal antibodies
  • Mechanism of Action Botulinum toxin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Clostridium difficile infections

Most Recent Events

  • 21 Apr 2018 Efficacy data from the phase III MODIFY I and II trials in Solid tumours presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
  • 20 Feb 2018 Phase-III clinical trials in Clostridium difficile infections (Adjuvant therapy, In children, In adolescents) in Germany, Hungary, Czech Republic, Sweden, Spain, Portugal, Poland, Norway, USA (IV) (NCT03182907)
  • 13 Nov 2017 Registered for Clostridium difficile infections (Prevention of relapse) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top